Russia's new HPV vaccine plant targets 90% infection rates in key regions

A new domestic HPV vaccine production facility opened in Russia's Kirov Region in autumn 2025. The move aims to boost vaccination rates as up to 90% of residents in nearby Nizhny Novgorod Region contract the virus at some point. Health officials continue to stress prevention and early awareness as key defences against infection. Human papillomavirus (HPV) spreads widely, with most infections showing no symptoms. Around 90% of cases go unnoticed, and the body often clears the virus naturally. Detection requires PCR testing, but mass screening remains unavailable.

Vaccination is now a priority, with the HPV jab approved for adults and children aged nine and older as of January 2026. Doctors strongly recommend childhood immunisation to reduce long-term risks. Once production in Kirov scales up, the vaccine is set to join Russia's National Immunization Schedule. As of March 2026, no reliable public data exists on how the Kirov facility has affected vaccination rates in Nizhny Novgorod Region. The plant is still in its early stages, and nationwide distribution is progressing gradually with limited regional reporting.

The new HPV vaccine facility marks a step toward wider immunisation access. Public health campaigns continue to highlight prevention as the best strategy against infection. Officials expect broader vaccine availability once full-scale production begins.